A Registry Study on Rimegepant for the Treatment of Migraine Participants in Guangdong-Hong Kong-Macao Greater Bay Area

Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study ID
NCT06221267
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Rimegepant — DRUG
    No intervention. The study will record the usage, timing, frequency, and dosage of rimegepant in a real-world clinical setting.

Study Details

This study is a single-arm, prospective, multicenter, observational registry study. It plans to enroll 120 migraine patients who meet the inclusion criteria and are treated with rimegepant in selected hospital outpatient clinics in the Greater Bay Area. The main purpose of this study is to observe the effectiveness of rimegepant in treating migraines in a real-world clinical setting, including the impact of rimegepant on the quality of life, functioning, productivity status of migraine patients, and patients' satisfaction with the use of rimegepant in treating migraines.

Key Dates

Start date
Jan 26, 2024
Status verified
May 2026
Primary completion
Jun 30, 2024
Completion
Jun 30, 2024

Study Design

Enrollment
120 participants (actual)

Primary Outcome Measure

Treatment Satisfaction Questionnaire for Medication (TSQM) [ Time Frame: 4 weeks ]

Related Studies